ACS Pharmacology & Translational Science

ACS Pharmacology & Translational Science is an open-access, online-only journal published by the American Chemical Society that reports advances across basic, molecular and translational pharmacology, from preclinical studies to clinical trials, and its 2025 Journal Impact Factor is 4.0《ACS 药理学与转化科学》是（American Chemical Society）出版的开放获取纯在线期刊，报道基础、分子与转化药理学的进展，从前临床研究延伸至临床试验，2025 年影响因子为 4.0。

Scope

• The journal publishes high-quality, innovative research across the broad spectrum of the biological sciences, from basic and molecular science through to translational preclinical studies该刊发表横跨生物科学广阔领域的高质量创新研究，从基础与分子科学延伸至转化前临床研究。
• Work that integrates basic pharmacological or biochemical findings into physiological processes with translational potential is given priority该刊优先考虑把基础药理学或生物化学发现整合进具有转化潜力的生理过程的研究。
• Clinical studies that address novel mechanisms of action and methodological papers that advance translation are also considered探讨新作用机制的临床研究以及推动转化方法学的论文同样在考虑之列。
• Its coverage spans all therapeutic areas and molecular targets rather than a single drug class其覆盖范围涵盖所有治疗领域与分子靶点，而非单一的药物类别。
• Article types include original research, reviews and perspectives on drug discovery and development文章类型包括原创研究、综述以及关于药物发现与开发的展望。
• The journal supports open science, encouraging data and code sharing alongside publication该刊支持开放科学，鼓励在发表的同时共享数据与代码。

History

• ACS Pharmacology & Translational Science was launched by the American Chemical Society, with its first issue appearing in 2019《ACS 药理学与转化科学》由（American Chemical Society）创办，首期于 2019 年面世。
• It was created to fill a gap in the society's biological portfolio by covering pharmacology and translational science across therapeutic areas该刊的创办填补了学会生物学期刊组合中的空白，覆盖各治疗领域的药理学与转化科学。
• It is published online only and operates on a continuous publication model该刊仅在线出版，采用连续出版模式。
• The journal received its first partial impact factor in 2023, reported at 6.0 at the time该刊于 2023 年获得首个影响因子，当时报告为 6.0。
• It is indexed in the Emerging Sources Citation Index and Scopus该刊被（Emerging Sources Citation Index）与（Scopus）收录。
• Its 2025 Journal Impact Factor is 4.0, following 3.7 in 2024该刊 2025 年影响因子为 4.0，2024 年为 3.7。

Editors

• The Editor-in-Chief is Christa E. Müller of the University of Bonn in Germany主编为（Christa E. Müller），任职于德国波恩大学。
• She took up the role in 2021, succeeding the interim leadership that guided the journal's early years她于 2021 年出任该职，接替此前指导期刊初创阶段的临时领导团队。
• An international editorial board covers medicinal chemistry, pharmacology and translational medicine国际化的编委会覆盖药物化学、药理学与转化医学。
• Manuscripts are peer reviewed, and prospective authors correspond with the journal through its editorial office稿件实行同行评审，潜在作者通过编辑部与期刊联系。
• As an ACS title it follows the society's policies on research ethics and data作为（ACS）旗下期刊，它遵循该学会关于科研伦理与数据的政策。